Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency
- 1 July 2001
- journal article
- Published by Elsevier BV in The Journal of Pediatrics
- Vol. 139 (1), 44-50
- https://doi.org/10.1067/mpd.2001.115023
Abstract
The objective was to evaluate the cognitive, behavioral, and neurodevelopmental function in patients with adenosine deaminase deficient severe combined immunodeficiency (ADA-SCID) and to compare the findings with those of a case control group of patients without ADA-SCID. Case-matched pairs of patients with ADA-SCID (n = 11) and patients without ADA-SCID who had undergone bone marrow transplantation were recruited. Subjects were assessed by age-appropriate standard tests of intelligence, behavior, and neurodevelopment. Cognitive ability was not significantly different between the 2 groups, but patients with ADA-SCID showed a significant inverse correlation between deoxyadenosinetrisphosphate levels at diagnosis and IQ (P =.048). Behavioral assessment showed that patients with ADA-SCID functioned in the pathologic range on all domains, whereas mean scores for the control group were within normal limits. Behavioral impairment in patients with ADA-SCID also showed a significant positive correlation with age (P =.026). Cognitive function in ADA deficiency is adversely affected by the severity of metabolic derangement at the time of diagnosis. In addition, patients with ADA-SCID have significant behavioral abnormalities after transplantation. These defects are not due to the transplant procedure but reflect the systemic nature of ADA deficiency. These findings have important implications for future medical and nonmedical management strategies.Keywords
This publication has 26 references indexed in Scilit:
- Sensorineural deafness in siblings with adenosine deaminase deficiencyBrain & Development, 1996
- PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 yearsClinical Immunology and Immunopathology, 1995
- p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency.Proceedings of the National Academy of Sciences of the United States of America, 1995
- PEG-ADA: An alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiencyHuman Mutation, 1995
- Overview of Biochemical Abnormalities and Molecular Genetics of Adenosine Deaminase DeficiencyPediatric Research, 1993
- European experience of bone-marrow transplantation for severe combined immunodeficiencyThe Lancet, 1990
- Effects of deoxyadenosine on ribonucleotide reductase in adenosine deaminase‐deficient lymphocytesJournal of Inherited Metabolic Disease, 1990
- Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminaseBritish Journal of Haematology, 1984
- Amelioration of Neurologic Abnormalities after Enzyme Replacement in Adenosine Deaminase DeficiencyNew England Journal of Medicine, 1980
- The chondro-osseous dysplasia of adenosine deaminase deficiency with severe combined immunodeficiencyThe Journal of Pediatrics, 1976